Pfizer Forgoes Fees To Close Accupril Suit
A Pfizer Inc. subsidiary has ended its decade-old dispute with Teva Pharmaceuticals USA Inc. over the hypertension drug Accupril by dropping attorneys' fees and willful infringement claims in exchange for Teva...To view the full article, register now.
Already a subscriber? Click here to view full article